Clinical trial
A Study to Evaluate the Safety and Efficacy of a Single Dose of Gruticibart for the Prevention of Early Catheter-related Thrombosis
NCT07498517 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study to Evaluate the Safety and Efficacy of a Single Dose of Gruticibart for the Prevention of Early Catheter-related Thrombosis
- Lead sponsor
- OHSU Knight Cancer Institute
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 6, 2026
- Completion date
- October 2, 2029
- Enrollment
- 90 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.